Supernus Pharmaceuticals, Inc. | Business Contracts

Settlement Agreement, dated as of December 31, 2022, by and between Supernus Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited (Filed With SEC on March 9, 2023)

Exhibit 10.1 Credit Line Agreement between UBS Bank USA and Supernus Pharmaceuticals, Inc. dated as of February 8, 2023 (Filed With SEC on February 14, 2023)

Amendment to Deed of Lease, August 23, 2021, by and between Supernus Pharmaceuticals, Inc. and Key West MD Owner, LLC (Filed With SEC on November 5, 2021)

Agreement and Plan of Merger, dated as of October 10, 2021, by and among Supernus Pharmaceuticals, Inc., Supernus Reef, Inc. and Adamas Pharmaceuticals, Inc (Filed With SEC on October 12, 2021)

Form of Performance Share Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 6, 2021)

Exhibit 10.1+ Offer Letter to Timothy C. Dec (Filed With SEC on July 29, 2021)

Exclusive License Agreement, dated as of June 6, 2006, by and between the Registrant and United Therapeutics Corporation (Filed With SEC on March 8, 2021)

Form of Restricted Stock Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 6, 2021)

Form of Non-Statutory Time-Based Stock Option Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 6, 2021)

Form of Time-Based Incentive Stock Option Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 6, 2021)

API Supply Agreement, dated July 13, 2021, by and between Supernus Pharmaceuticals, Inc. and Bachem Americas, Inc (Filed With SEC on August 6, 2021)

Commercial Supply Agreement, dated May 12, 2021, by and between Supernus Pharmaceuticals, Inc. and Catalent Pharma Solutions, LLC (Filed With SEC on August 6, 2021)

Purchase and Sale Agreement, dated as of June 9, 2006, by and between the Registrant and Rune HealthCare Limited (Filed With SEC on March 8, 2021)

Guanfacine License Agreement, dated as of December 22, 2005, by and among the Registrant, Shire LLC and Shire plc, as amended (Filed With SEC on March 8, 2021)

Asset Purchase and Contribution Agreement, dated as of December (Filed With SEC on March 8, 2021)

Consulting Agreement, made as of December 31, 2020, by and between the Company (Filed With SEC on November 19, 2020)

Consulting Agreement, made as of November 18, 2020, by and between the Company (Filed With SEC on November 19, 2020)

EXECUTIVE RETENTION AGREEMENT (Filed With SEC on October 5, 2020)

Offer Letter to James P. Kelly (Filed With SEC on October 5, 2020)

Exhibit 10.2+ Form of Performance Share Unit Award Agreement, issued under the Amended and Restated Stock Incentive Plan, for grants made to Jack A. Khattar, as an Exhibit... (Filed With SEC on February 27, 2020)

Exhibit 10.1+ Form of Restricted Stock Unit Award Agreement for Non-Management Directors, issued under the Supernus Pharmaceuticals, Inc., 2012 Equity Incentive Plan, as amended,... (Filed With SEC on February 27, 2020)

Press Release Dated September 25, 2019 (Filed With SEC on September 25, 2019)

Press Release Dated August 26, 2019 (Filed With SEC on August 26, 2019)

Press Release Dated July 23, 2019 (Filed With SEC on July 23, 2019)

Lease Agreement Dated January 31, 2019 (Filed With SEC on February 5, 2019)

Supernus Pharmaceuticals, Inc. (25)